These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 1857424)

  • 1. Radioactive cell membrane labelling.
    Slezak SE; Muirhead KA
    Nature; 1991 Jul; 352(6332):261-2. PubMed ID: 1857424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of lymphokine-activated killer cells in long-term cultures.
    Hartwig M; Körner IJ
    Immunology; 1990 Sep; 71(1):145-7. PubMed ID: 2210801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA-protein cell content of lymphokine activated killer (LAK) and target cells in coculture.
    Nano R; Barni S; Capelli E; Prosperi E; Lavezzi L; Salvucci O
    Anticancer Res; 1995; 15(3):751-4. PubMed ID: 7645953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypical study of human lymphokine-activated killer (LAK) cells.
    Barral AM; García CA
    Neoplasma; 1989; 36(5):583-8. PubMed ID: 2682296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo.
    Berthold F; Himmelmann U; Pohl U
    Prog Clin Biol Res; 1991; 366():417-24. PubMed ID: 1906185
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
    Dannemann BR; Morris VA; Araujo FG; Remington JS
    J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of function-associated molecules in target cell lysis: analysis of rat adherent lymphokine-activated killer cells.
    Jaso-Friedmann L; Leary JH; Evans DL
    Nat Immun; 1993; 12(6):316-25. PubMed ID: 8268715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killing capacity of LAK cell transduced lymphocytes harvested by Haemonetics V50 lymphosurge technique.
    Elias MK; de Ley L; Smit Sibinga CT; Das PC
    Prog Clin Biol Res; 1990; 337():469-76. PubMed ID: 2353008
    [No Abstract]   [Full Text] [Related]  

  • 12. Cell membrane labeling with fluorescent dyes for the demonstration of cytokine-induced fusion between monocytes and tumor cells.
    Spötl L; Sarti A; Dierich MP; Möst J
    Cytometry; 1995 Oct; 21(2):160-9. PubMed ID: 8582236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of cell surface structures involved in cytotoxicity mediated by lymphokine activated killer cells.
    Bean P; Agah R; Mazumder A
    J Biol Response Mod; 1990 Feb; 9(1):92-7. PubMed ID: 2181073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ultraviolet B irradiation on human natural killer cell and lymphokine activated killer cell activity: therapeutic potential in bone marrow transplantation and tumor immunotherapy.
    Yaron I; Zakheim AR; Oluwole SF; Hardy MA
    Transplant Proc; 1995 Feb; 27(1):1379. PubMed ID: 7878918
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of target molecule of murine lymphokine-activated killer (LAK) cells and the clones.
    Hashimoto Y; Kato K; Sato N; Yagi H; Yagita H; Nishimura T
    Princess Takamatsu Symp; 1988; 19():315-22. PubMed ID: 3077625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased sensitivity of gastric cancer cells to natural killer and lymphokine-activated killer cells by antisense suppression of N-acetylgalactosaminyltransferase.
    Adachi T; Hinoda Y; Nishimori I; Adachi M; Imai K
    J Immunol; 1997 Sep; 159(6):2645-51. PubMed ID: 9300683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of Gc (vitamin-D binding protein) with membrane of activated natural cytolytic cells.
    Ades EW; Bosse D; Nicholson JK; Galbraith R
    Tokai J Exp Clin Med; 1988 Dec; 13(6):293-7. PubMed ID: 3273473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
    Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
    J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of recombinant human IL-2 in miniature swine.
    Nakajima K; Smith CV; Mixon A; Rosengard BR; Guzzetta PC; Spitzer TR; Eckhaus MA; Sachs DH
    Transplant Proc; 1991 Feb; 23(1 Pt 1):248-50. PubMed ID: 1990524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.